Source - LSE Regulatory
RNS Number : 8452I
Alliance Pharma PLC
10 August 2023
 

For immediate release

10 August 2023

 

 

ALLIANCE PHARMA PLC

("Alliance", "Company" or the "Group")

 

Notification of Half Year Results

 

Alliance Pharma plc (AIM: APH), the international consumer healthcare company, announces a change of date for the publication of its results for the six months ended 30 June 2023. The interim results will be released on Tuesday 26 September 2023.

 

A meeting for analysts will be held at 9:30am on 26 September 2023 at Buchanan, 107 Cheapside, London EC2V 6DN. To register for the meeting, analysts should contact Buchanan at alliancepharma@buchanan.uk.com.

 

A live webcast of the analyst meeting will be accessible via the following link:

https://stream.buchanan.uk.com/broadcast/64d35bfa8964824b00aaa7a0

 

Following the meeting, a replay of the webcast will be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors/,

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

 

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

 

alliancepharma@buchanan.uk.com

 

 

 

Numis Securities Limited (Nominated Adviser and Joint Broker)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah

 

 

 

Investec Bank plc (Joint Broker)

+ 44 (0)20 7597 5970

Patrick Robb / Maria Gomez de Olea

 

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSSFFIUEDSEDA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Alliance Pharma PLC (APH)

+0.25p (+0.71%)
delayed 15:56PM